DuBois SG, et al. - Researchers characterized the clinical course of locally advanced tropomyosin receptor kinase (TRK) fusion sarcoma in children treated preoperatively with larotrectinib and who had subsequent surgical resection. Outcomes suggest that after treatment with the selective TRK inhibitor larotrectinib, these children could go on to have surgical resection, which may reduce the possibly significant morbidity seen with current approaches. In children with newly diagnosed TRK fusion sarcomas, the data support the assessment of larotrectinib as presurgical therapy.